



Press Release

MSN Labs received tentative approval for its abbreviated new drug application (ANDA) of Cangrelor from USFDA.

Hyderabad, 16th December 2021: Close on the heels of securing DCGI's approval for **CANREAL™** injection (generic version of Cangrelor) in India, MSN Laboratories, one of the India's leading, fully integrated and research-based pharmaceutical organizations has now received tentative approval for its generic version of Cangrelor from USFDA.

MSN Group commented: "Besides reflecting the capability of MSN Laboratories to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US."

It will be manufactured at a FDA and MHRA approved state-of-the-art injectable facility in Hyderabad.

END

About MSN Group:

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has more than 823 national and international patents filed, over 130 ANDAs, and emerged as world no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning 35 major therapies, has won the trust of more than 40 million patients in 65 countries across the world.

For information on MSN Labs, please visit www.msnlabs.com